BNP Paribas Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.2B Sell
1,001,608
-155,868
-13% -$159M 1.2% 13
2026
Q1
$1.06B Buy
1,157,476
+220,151
+23% +$223M 1.24% 10
2025
Q4
$1.01B Buy
937,325
+272,078
+41% +$260M 1.16% 10
2025
Q3
$507M Buy
665,247
+164,846
+33% +$123M 1.31% 9
2025
Q2
$390M Sell
500,401
-147,142
-23% -$114M 0.95% 14
2025
Q1
$535M Buy
647,543
+181,897
+39% +$151M 1.43% 7
2024
Q4
$359M Sell
465,646
-127,556
-22% -$106M 0.89% 16
2024
Q3
$526M Sell
593,202
-101,924
-15% -$91.6M 1.3% 7
2024
Q2
$629M Sell
695,126
-2,765
-0.4% -$2.21M 1.63% 7
2024
Q1
$543M Sell
697,891
-47,979
-6% -$34.1M 1.44% 7
2023
Q4
$435M Sell
745,870
-131,385
-15% -$76.7M 1.21% 10
2023
Q3
$471M Buy
877,255
+195,977
+29% +$101M 1.44% 8
2023
Q2
$320M Buy
681,278
+62,507
+10% +$26.2M 0.99% 14
2023
Q1
$212M Sell
618,771
-129,903
-17% -$43.8M 0.74% 22
2022
Q4
$274M Buy
748,674
+109,601
+17% +$38.9M 0.98% 11
2022
Q3
$207M Sell
639,073
-135,605
-18% -$43M 0.81% 21
2022
Q2
$251M Buy
774,678
+10,275
+1% +$3.08M 0.96% 13
2022
Q1
$219M Sell
764,403
-15,681
-2% -$4.04M 0.76% 23
2021
Q4
$215M Buy
780,084
+73,333
+10% +$18.6M 0.72% 23
2021
Q3
$163M Buy
706,751
+78,008
+12% +$19.3M 0.61% 27
2021
Q2
$144M Sell
628,743
-62,284
-9% -$12.5M 0.51% 39
2021
Q1
$129M Buy
691,027
+18,760
+3% +$3.67M 0.53% 40
2020
Q4
$114M Buy
672,267
+77,879
+13% +$11.6M 0.52% 34
2020
Q3
$88M Buy
594,388
+252,955
+74% +$39.1M 0.5% 40
2020
Q2
$56.1M Buy
341,433
+60,734
+22% +$9.32M 0.38% 60
2020
Q1
$38.9M Buy
280,699
+120,005
+75% +$16.5M 0.33% 74
2019
Q4
$21.1M Sell
160,694
-191,871
-54% -$22.2M 0.14% 198
2019
Q3
$39.4M Buy
352,565
+49,529
+16% +$5.51M 0.3% 83
2019
Q2
$33.6M Buy
303,036
+97,399
+47% +$11.5M 0.27% 93
2019
Q1
$26.7M Buy
205,637
+3,747
+2% +$456K 0.22% 114
2018
Q4
$23.1M Buy
201,890
+10,192
+5% +$1.14M 0.21% 133
2018
Q3
$20.6M Sell
191,698
-6,025
-3% -$602K 0.16% 183
2018
Q2
$16.9M Buy
197,723
+540
+0.3% +$44.4K 0.14% 198
2018
Q1
$15.3M Sell
197,183
-62,937
-24% -$5.07M 0.13% 219
2017
Q4
$22M Sell
260,120
-244,592
-48% -$20.8M 0.19% 141
2017
Q3
$43.2M Sell
504,712
-254,291
-34% -$20.9M 0.37% 57
2017
Q2
$62.5M Sell
759,003
-22,027
-3% -$1.8M 0.55% 26
2017
Q1
$65.7M Sell
781,030
-19,955
-2% -$1.6M 0.6% 25
2016
Q4
$58.9M Buy
800,985
+169,272
+27% +$12.6M 0.57% 30
2016
Q3
$50.7M Buy
631,713
+147,594
+30% +$11.8M 0.43% 48
2016
Q2
$38.1M Sell
484,119
-66,332
-12% -$4.99M 0.32% 73
2016
Q1
$39.6M Buy
550,451
+224,293
+69% +$17M 0.34% 69
2015
Q4
$27.5M Sell
326,158
-41,767
-11% -$3.47M 0.23% 113
2015
Q3
$30.8M Sell
367,925
-11,349
-3% -$958K 0.27% 94
2015
Q2
$31.7M Buy
379,274
+132,946
+54% +$10.1M 0.26% 99
2015
Q1
$17.9M Buy
246,328
+78,944
+47% +$5.62M 0.14% 215
2014
Q4
$11.5M Buy
167,384
+7,021
+4% +$474K 0.09% 279
2014
Q3
$10.4M Sell
160,363
-91,724
-36% -$5.81M 0.08% 271
2014
Q2
$15.7M Buy
252,087
+20,323
+9% +$1.21M 0.12% 216
2014
Q1
$13.6M Sell
231,764
-81,671
-26% -$4.56M 0.1% 231
2013
Q4
$16M Sell
313,435
-141,695
-31% -$7.1M 0.12% 219
2013
Q3
$22.9M Buy
455,130
+3,470
+0.8% +$182K 0.17% 176
2013
Q2
$22.2M Buy
+451,660
New +$24.6M 0.16% 172

Other funds holding LLY

BNP Paribas Asset Management's LLY Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Eli Lilly (LLY) stake by 13% in Q2 2026, selling an estimated $159M and leaving 1,001,608 shares worth $1.2B. The position accounts for 1.2% of the portfolio, ranked #13.

BNP Paribas Asset Management first reported a position in LLY in Q2 2013 and has held it in 53 quarters since. 4,593 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • BNP Paribas Asset Management held 1,001,608 shares of Eli Lilly worth $1.2B as of Q2 2026.
  • BNP Paribas Asset Management sold 155,868 Eli Lilly shares in Q2 2026, an estimated $159M.
  • Eli Lilly made up 1.2% of BNP Paribas Asset Management's portfolio in Q2 2026, its #13 holding.
  • BNP Paribas Asset Management first reported a position in Eli Lilly in Q2 2013 and has held it in 53 quarters since.
  • 4,593 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.